Myeloma Research Group
Our group explores novel therapeutic approaches for multiple myeloma (MM) in preclinical and clinical studies.
We are evaluating the activity and mechanism of action of epigenetic modifying agents as well as undertaking preclinical development of both a novel anti-MM monoclonal antibody, Mab, and the orally bioavailable-catenin inhibitor BC2059.
We secured funding from the Victorian Cancer Agency, International Myeloma Foundation and pharmaceutical industry partners and activated the Myeloma and Related Diseases Registry aligned national biobanking initiative, the Myeloma 1000 Project.
